CIDP vs Guillain-Barré Syndrome: Key Differences

GBS (Guillain-Barré syndrome) and CIDP (chronic inflammatory demyelinating polyneuropathy) are both autoimmune conditions that damage the myelin sheath of peripheral nerves, causing weakness and sensory loss. The critical difference is timing: GBS reaches its worst point within 4 weeks and then typically improves; CIDP progresses over more than 8 weeks and either continues to worsen or relapses relentlessly over years. This time-course distinction directly determines treatment — IVIG and plasmapheresis are used for both, but corticosteroids work for CIDP and are ineffective, possibly harmful, for GBS.

This explainer draws on published research from three neurologists in the Convene directory: Thomas Brannagan, M.D., Professor of Neurology at Columbia University and Director of the Peripheral Neuropathy Center at NewYork-Presbyterian, whose work includes IVIG complications in autoimmune neuromuscular disease; Michael Rowbotham, M.D., at UCSF, whose NeuPSIG guidelines and IASP classification work established the framework for categorizing neuropathic pain — a major burden in both CIDP and GBS; and Eva Feldman, M.D., Ph.D., at Michigan Medicine, whose quantitative electrophysiological methods for diagnosing and staging neuropathy underpin the nerve conduction criteria used to distinguish demyelinating from axonal disease [1][2][3][4][5][6].

What both conditions share

Both GBS and CIDP are immune-mediated polyneuropathies. In each condition, the immune system mistakenly targets myelin — the insulating sheath that enables fast, reliable nerve conduction — along peripheral nerve fibers. The clinical consequences overlap substantially: ascending weakness that typically starts in the legs and works upward, reduced or absent deep tendon reflexes (hyporeflexia or areflexia), and sensory disturbances including numbness, tingling, and, in many patients, neuropathic pain.

The cerebrospinal fluid (CSF) profile is similar in both conditions: elevated protein with a normal or near-normal white cell count, a pattern called albuminocytologic dissociation. This finding reflects protein leaking from inflamed nerve roots into the CSF without the cellular infiltrate of infection or malignancy.

Nerve conduction studies (NCS) are the cornerstone of electrodiagnostic workup for both conditions and show a characteristic demyelinating pattern: slowed conduction velocities, prolonged distal latencies, prolonged or absent F-waves, and — critically — conduction block and temporal dispersion. Eva Feldman's electrophysiological staging methods, validated in diabetic neuropathy research, illustrate how precisely quantified NCS findings can distinguish demyelinating from axonal injury patterns [5][6]. Diabetic neuropathy, for example, is predominantly axonal — amplitudes are reduced but velocities are relatively preserved. The demyelinating slowing seen in GBS and CIDP represents a fundamentally different pathophysiology: the myelin is being stripped away, not the axon itself damaged.

The defining difference: time course

The 8-week rule is the diagnostic pivot. GBS is an acute condition: weakness and other symptoms progress rapidly, reaching their nadir within 4 weeks in virtually all patients (and within 2 weeks in the majority). After the nadir, patients plateau and then — in most cases — recover over weeks to months. The total illness arc from onset to substantial recovery typically spans 3 to 6 months.

CIDP is defined by progression that continues beyond 8 weeks. A patient who is still deteriorating at the 8-week mark — or who has improved and then relapsed — should be evaluated for CIDP. The 8-week threshold is not arbitrary: it reflects the clinical observation that the immune process driving CIDP does not self-limit the way GBS typically does.

This matters for treatment. Both the Rowbotham-led NeuPSIG guidelines and the IASP classification of chronic neuropathic pain for ICD-11 recognize chronic inflammatory neuropathies including CIDP as established causes of neuropathic pain — a burden that persists long after the acute phase in both conditions [3][4]. But the treatment strategies diverge at the diagnostic boundary. For GBS, corticosteroids have been tested in multiple randomized trials and shown to be ineffective — they do not speed recovery and may slightly worsen outcomes. For CIDP, corticosteroids are one of three evidence-based treatments alongside IVIG and plasma exchange, and they remain the most cost-effective long-term option for many patients.

Comparison table

GBS: what to know

Guillain-Barré syndrome affects approximately 1 to 2 people per 100,000 per year. It is the most common cause of acute flaccid paralysis in countries where poliovirus has been eliminated. The trigger is usually an infection that occurred 1 to 3 weeks before symptom onset. Campylobacter jejuni gastroenteritis is the most common identified trigger; cytomegalovirus, Epstein-Barr virus, Zika virus, influenza, and COVID-19 have all been associated with GBS.

The most common subtype in the United States and Western Europe is acute inflammatory demyelinating polyneuropathy (AIDP), which accounts for roughly 85 to 90% of GBS cases in these regions. Two axonal subtypes — acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) — are more common in East Asia and tend to follow Campylobacter infection. A third recognized variant, Miller Fisher syndrome, presents with a triad of ophthalmoplegia, ataxia, and areflexia rather than limb weakness; it is associated with the anti-GQ1b antibody and generally carries a good prognosis.

Treatment in the acute phase consists of either IVIG (2 g/kg given over 2 to 5 days) or plasma exchange (typically 5 exchanges over 1 to 2 weeks). Both have been shown in randomized trials to be equally effective at accelerating recovery. They are not additive — combining them after one has been given does not improve outcomes further. Corticosteroids, as noted, do not help.

Brannagan's experience with IVIG in autoimmune neuromuscular disease, and his 1996 paper in Neurology on complications of intravenous immunoglobulin therapy in neurological disease, highlights the practical monitoring considerations: thrombotic events, renal impairment (especially with sucrose-containing preparations), aseptic meningitis, and hemolysis [2]. These are uncommon but real risks that warrant monitoring, particularly in patients with cardiovascular disease or renal insufficiency.

Outcomes for GBS are generally favorable. Approximately 80% of patients are walking independently at 6 months. However, about 20% remain significantly disabled, and 5% die despite treatment — usually from respiratory failure, autonomic instability, or secondary complications. The single greatest risk in the acute phase is respiratory failure: up to 25 to 30% of hospitalized GBS patients require mechanical ventilation.

CIDP: what to know

Chronic inflammatory demyelinating polyneuropathy has an estimated prevalence of roughly 5 per 100,000 — higher than GBS because it is a chronic condition that accumulates cases over time. Unlike GBS, most patients with CIDP have no identifiable infectious or environmental trigger; it appears to arise from a breakdown in immune tolerance to peripheral nerve antigens.

CIDP is not a single entity but encompasses several clinical variants. Typical CIDP involves symmetric proximal and distal weakness in all four limbs with sensory involvement. Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM, or Lewis-Sumner syndrome) presents asymmetrically with patchy involvement. Pure sensory CIDP affects sensation without meaningful motor weakness. These subtypes have overlapping but not identical responses to treatment, and distinguishing them from other neuropathies — including hereditary demyelinating neuropathies like Charcot-Marie-Tooth disease — requires careful electrodiagnostic and, increasingly, genetic workup.

Treatment for CIDP is long-term for most patients. All three first-line options — IVIG, plasma exchange, and corticosteroids — have high-quality trial support. The choice often depends on practicality: IVIG and plasma exchange provide faster symptomatic improvement, while corticosteroids are slower to act but easier to administer long-term and dramatically cheaper. Subcutaneous immunoglobulin (SCIg) has emerged as a maintenance option for patients who respond to IVIG; it can be self-administered at home and has equivalent efficacy with a more stable serum IgG profile. Approximately 30% of CIDP patients achieve sustained remission; the remainder require ongoing therapy, often for years.

IVIG: shared treatment, different goals

Intravenous immunoglobulin is used in both conditions, but what it accomplishes differs. In GBS, IVIG accelerates recovery — patients who receive it reach their nadir faster, recover faster, and spend fewer days on a ventilator. But it does not meaningfully change long-term disability at 6 or 12 months. The goal is to shorten the acute illness, not to cure an ongoing process.

In CIDP, IVIG is maintenance therapy. Because the immune process does not self-limit, patients who respond to IVIG typically need repeat infusions every 3 to 6 weeks indefinitely to prevent relapse. The dose and interval are titrated against clinical response — strength, sensory function, and quality of life — rather than against a laboratory marker.

Brannagan's 1996 Neurology paper on IVIG complications in neurological disease remains a useful clinical reference for the practical risks of high-dose IVIG that accumulates over the long treatment courses typical of CIDP [2]: thrombotic complications including deep vein thrombosis, pulmonary embolism, and stroke (related to the transient increase in blood viscosity after infusion); renal impairment (largely mitigated by using sucrose-free preparations); aseptic meningitis (rare, usually self-limiting); and hemolytic anemia (more common at high doses). For CIDP patients receiving IVIG every month for years, the cumulative risk warrants periodic monitoring of renal function and baseline cardiovascular risk assessment [1].

Electrodiagnostic criteria

Nerve conduction studies are not merely supportive in CIDP and GBS — they are often required for diagnosis. The European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIDP require specific NCS findings: conduction velocity reduction to below a defined threshold, prolonged distal latencies, prolonged F-wave latencies, and the presence of conduction block or temporal dispersion in at least two nerves.

Eva Feldman's work on quantitative, two-step electrophysiological assessment for staging neuropathy provides important context for why these criteria matter [5][6]. Her research demonstrated that NCS abnormalities correlate with clinical severity and can be used to track disease progression over time. In demyelinating conditions like CIDP, slowed velocities reflect myelin loss; as myelin regenerates or inflammation is controlled, velocities improve. In axonal neuropathies — including diabetic neuropathy — velocities may be near-normal while amplitudes are reduced, reflecting a fundamentally different injury mechanism.

This distinction matters clinically. Diabetes is common, and many patients with CIDP also have diabetes. The presence of diabetes does not cause the CIDP picture. Axonal diabetic neuropathy and superimposed demyelinating CIDP can coexist, and untreated CIDP can be mistakenly attributed to diabetes. Careful electrodiagnostic analysis — looking for the specific demyelinating features of conduction block, temporal dispersion, and markedly prolonged F-waves — is what separates the two.

When to go to the ER vs see a neurologist

If symptoms suggest GBS — rapidly progressive weakness in the legs that is spreading upward, difficulty breathing or swallowing, loss of balance, or rapidly worsening numbness over days — go to the emergency room immediately. GBS can progress to respiratory failure within hours to days. Hospitalization with close respiratory monitoring is required.

If symptoms suggest CIDP — progressive weakness and sensory symptoms developing over weeks, with no respiratory emergency — the appropriate setting is an urgent neurology appointment. There is time for a thoughtful workup including nerve conduction studies, lumbar puncture, and labs. That said, any weakness or numbness that involves breathing muscles, the face, or the throat should be evaluated in an emergency setting regardless of suspected diagnosis.

Questions to ask your neurologist

• Is my nerve conduction study showing a demyelinating pattern, an axonal pattern, or a mixed picture — and what does that mean for diagnosis?
• How long have my symptoms been progressing, and does the time course point toward GBS, CIDP, or something else?
• If CIDP is the diagnosis, which treatment — IVIG, plasma exchange, or corticosteroids — would you recommend starting with, and why?
• How will we know whether treatment is working, and what is the plan if the first treatment is not effective?
• Are there any clinical trial options available for my condition, particularly if standard treatments provide inadequate relief?

The bottom line

GBS and CIDP are related but fundamentally different conditions: GBS is a self-limiting acute emergency that peaks within 4 weeks and usually resolves, while CIDP is a chronic relapsing-remitting or progressive neuropathy that requires long-term treatment. The 8-week threshold is the diagnostic dividing line, and it is clinically important because it determines whether corticosteroids are appropriate. Both conditions are treatable — GBS with IVIG or plasma exchange to accelerate recovery, CIDP with a broader range of maintenance options — and early diagnosis by a neurologist with experience in neuromuscular disease is the most important factor in achieving the best outcome.